Boston Scientific accounts are for healthcare professionals only.
Varithena™ (polidocanol injectable foam) 1%
Reimbursement
- Overview
- Clinical Data
- Technical Specifications
- Ordering information
- Training
- Resources
One thing can be a meaningful addition for your patients and your practice.
Varithena is the only FDA-approved foam indicated for treating chronic venous insufficiency (CVI), using a non-thermal, non-tumescent approach for the great saphenous vein (GSV) system and its associated veins. Its patented Microfoam UDSS™ technology produces a cohesive, low-nitrogen microfoam (O2:CO2 ratio of 65:35 with <0.8% nitrogen) and takes approximately 10 minutes to administer. The microfoam fills the vein lumen for circumferential contact, displacing blood and efficiently destroying the endothelial lining.
Varithena mechanism of action explained
- Incompetent tributaries can be treated through either one injection site, or when warranted, multiple injection sites.
- A column of microfoam advances to fill the vein.
- Varithena displaces blood, effectively filling the lumen for circumferential contact.1
- Varithena achieves endothelial destruction with very low polidocanol concentration.
- The vein contracts, narrowing the lumen until vein has almost no volume.
- Residual, low-nitrogen bubbles are highly absorbable in blood and are swept away and absorbed in venous circulation.
Add versatility to your practice.
GSV above and below the knee, tortuosity, recanalization, large and small veins C2-C6. Treat them all with Varithena.
- Recurrent veins
- Above and below the knee
- Recanalization
- Wide range of diameters up to 25.9 mm
- Tortuosity
Interested in adding Varithena to your practice?
Learn more about becoming Varithena certified.
References:
1. Eckmann DM. Polidocanol for endovenous microfoam sclerosant therapy. Expert Opin Investig Drugs. 2009 Dec;18(12):1919-27. doi: 10.1517/13543780903376163.
